Towards Healthcare
Strongyloidiasis Treatment Market 2025 Surges with 4.5% CAGR as WHO Backs Iver...

Strongyloidiasis Treatment Market 2025 Updates New Diagnostic Launches and Global Drug Access Programs

Market insights predict, the strongyloidiasis treatment industry is expected to grow from USD 1.1 billion in 2024 to USD 1.72 billion by 2034, driven by a CAGR of 4.5%. The market is growing due to increased global awareness and rising cases, especially among immunocompromised patients. Support from health organizations and wider access to ivermectin are further boosting market demand.

Content

  • Insight Code: 5833
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The strongyloidiasis treatment market is projected to reach USD 1.72 billion by 2034, growing at a CAGR of 4.5% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.

The strongyloidiasis treatment market is projected to reach USD XX billion by 2034, growing at a CAGR of XX% from 2024 to 2034.

Latin America and sub-Saharan Africa are currently leading the healthcare cybersecurity market due to their high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission.

The strongyloidiasis treatment market includes six segments by drug type, by disease type, by route of administration, by end user, by distribution channel, and by region.

Some key players include Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., and Abbott Laboratories.

Key trends include the growth due to increased global awareness and rising cases, especially among immunocompromised patients.

Ivermectin is considered highly effective, with cure rates exceeding 90% in uncomplicated cases. It is the WHO-recommended drug for mass drug administration in endemic areas.

People with weakened immune systems such as organ transplant recipients, those on corticosteroids, or patients with HIV/AIDS are at greater risk of developing hyperinfection syndrome or disseminated strongyloidiasis, which can be fatal if untreated.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.
Any Questions